Navigation Links
SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
Date:7/29/2008

BELLEVUE, Wash., July 29 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (Amex: DDD) today announced plans to release second quarter 2008 financial results on Thursday, August 7, 2008, at 8:30 a.m. Eastern. Daniel O. Wilds, President and CEO of SCOLR Pharma, will host a conference call at 11:30 a.m. Eastern, to discuss the results.

Shareholders and other interested parties may participate in the conference call by dialing +1 888 680 0878 (domestic) or +1 617 213 4855 (international) and entering access code 26733631, a few minutes before 11:30 a.m. ET on August 7, 2008. The call will also be broadcast live on the Internet at http://www.streetevents.com, http://www.fulldisclosure.com or http://www.scolr.com.

A replay of the conference call will be accessible two hours after its completion through August 21, 2008, by dialing +1 888 286 8010 (domestic) or +1 617 801 6888 (international) and entering access code 55141034. The call will also be archived for 90 days at http://www.streetevents.com, http://www.fulldisclosure.com or http://www.scolr.com.

Based in Bellevue, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company. SCOLR Pharma's corporate objective is to combine its formulation expertise and its patented CDT platform to develop novel pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platform is based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425.373.0171 or visit http://www.scolr.com/.

Contact:

Investor Relations:

Cameron Associates

Kevin McGrath

212.245.4577

Kevin@cameronassoc.com


'/>"/>
SOURCE SCOLR Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
2. Meritage Pharma, Inc. Announces Company Formation and $22.5M Series A Financing
3. China Biopharma, Inc. Announces New Plan of Operation
4. Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
5. GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen
6. Volcano Corporation Schedules Second Quarter Conference Call, Webcast
7. Schering-Plough Reschedules Time of Conference Call, Webcast for 2008 Second Quarter Earnings to Later Today
8. Cepheid Schedules Fiscal 2008 Second Quarter Financial Results Announcement and Webcast
9. Schering-Plough Schedules Conference Call and Webcast for 2008 Second Quarter Earnings
10. Schering-Plough Schedules Webcast for Annual Meeting of Shareholders
11. ImaRx Schedules Release of First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
Breaking Biology Technology:
(Date:6/2/2016)... The Department of Transport Management (DOTM) ... million US Dollar project, for the , Supply ... Enrolment, and IT Infrastructure , to ... implementation of Identity Management Solutions. Numerous renowned international vendors participated ... was selected for the most compliant and innovative ...
(Date:6/1/2016)... 1, 2016 Favorable Government Initiatives ... and Criminal Identification to Boost Global Biometrics System Market ... TechSci Research report, " Global Biometrics Market By ... and Opportunities, 2011 - 2021", the global biometrics market ... on account of growing security concerns across various end ...
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
Breaking Biology News(10 mins):